Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kiora Pharmaceuticals ( (KPRX) ) has issued an announcement.
On April 3, 2026, Kiora Pharmaceuticals entered into a securities purchase agreement with institutional investors Perceptive Advisors and ADAR1 Capital Management for a private placement of common stock, pre-funded warrants, and milestone-based common warrants. The transaction, which closed on April 6, 2026 and was priced at-the-market under Nasdaq rules, delivers $5 million in upfront gross proceeds and could yield up to an additional $19 million if all warrants are exercised.
Under the deal, each share of common stock or pre-funded warrant was sold together with four Tranche A-1 and one Tranche A-2 warrant, all exercisable at $1.94 per share, with terms tied to strategic transactions and Phase 3 trial enrollment milestones. Kiora plans to use the initial proceeds for general corporate purposes, business development, and ongoing R&D, and has committed to register the resale of shares underlying the placement, reinforcing its funding base to advance its retinal disease pipeline without engaging a placement agent.
The most recent analyst rating on (KPRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kiora Pharmaceuticals stock, see the KPRX Stock Forecast page.
Spark’s Take on KPRX Stock
According to Spark, TipRanks’ AI Analyst, KPRX is a Neutral.
The score is primarily held down by weak TTM financial performance (zero revenue, sizable losses, and heavy cash burn). Technicals also lean bearish with the stock below key moving averages and negative MACD. Valuation further pressures the score due to a very high P/E and no dividend support.
To see Spark’s full report on KPRX stock, click here.
More about Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing advanced therapies for retinal diseases. Its pipeline includes KIO-301, a molecular photoswitch initially aimed at treating retinitis pigmentosa with potential expansion to choroideremia and Stargardt disease, and KIO-104, a non-steroidal small molecule targeting macular edema due to retinal inflammation.
The company focuses on innovative small molecules that target critical pathways underlying inherited and age-related retinal degeneration. By seeking to slow, stop, or restore vision loss in severely underserved ophthalmic conditions, Kiora is positioning itself within the niche market for vision-restorative and anti-inflammatory retinal treatments.
Average Trading Volume: 47,622
Technical Sentiment Signal: Sell
Current Market Cap: $7.98M
Find detailed analytics on KPRX stock on TipRanks’ Stock Analysis page.